nach oben

Erschienen in:

19.01.2024 | Diagnostic Neuroradiology

Atrophy of the cholinergic regions advances from early to late mild cognitive impairment

verfasst von: Ying-Liang Larry Lai, Fei-Ting Hsu, Shu-Yi Yeh, Yu-Tzu Kuo, Hui-Hsien Lin, Yi-Chun Lin, Li-Wei Kuo, Cheng-Yu Chen, Hua-Shan Liu, for the Alzheimer’s Disease Neuroimaging Initiative

Erschienen in: Neuroradiology | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We investigated the volumetric changes in the components of the cholinergic pathway for patients with early mild cognitive impairment (EMCI) and those with late mild cognitive impairment (LMCI). The effect of patients’ apolipoprotein 4 (APOE-ε4) allele status on the structural changes were analyzed.

Methods

Structural magnetic resonance imaging data were collected. Patients’ demographic information, plasma data, and validated global cognitive composite scores were included. Relevant features were extracted for constructing machine learning models to differentiate between EMCI (n = 312) and LMCI (n = 541) and predict patients’ neurocognitive function. The data were analyzed primarily through one-way analysis of variance and two-way analysis of covariance.

Results

Considerable differences were observed in cholinergic structural changes between patients with EMCI and LMCI. Cholinergic atrophy was more prominent in the LMCI cohort than in the EMCI cohort (P < 0.05 family-wise error corrected). APOE-ε4 differentially affected cholinergic atrophy in the LMCI and EMCI cohorts. For LMCI cohort, APOE-ε4 carriers exhibited increased brain atrophy (left amygdala: P = 0.001; right amygdala: P = 0.006, and right Ch123, P = 0.032). EMCI and LCMI patients showed distinctive associations of gray matter volumes in cholinergic regions with executive (R² = 0.063 and 0.030 for EMCI and LMCI, respectively) and language (R² = 0.095 and 0.042 for EMCI and LMCI, respectively) function.

Conclusions

Our data confirmed significant cholinergic atrophy differences between early and late stages of mild cognitive impairment. The impact of the APOE-ε4 allele on cholinergic atrophy varied between the LMCI and EMCI groups.

Nur mit Berechtigung zugänglich

Lin SY, Lin PC, Lin YC et al (2022) The Clinical Course of Early and Late Mild Cognitive Impairment. Front Neurol 13:685636PubMedPubMedCentralCrossRef

Morris JC, Storandt M, Miller JP et al (2001) Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 58:397–405PubMedCrossRef

Jessen F, Wolfsgruber S, Wiese B et al (2014) AD dementia risk in late MCI, in early MCI, and in subjective memory impairment. Alzheimers Dement 10:76–83PubMedCrossRef

Aisen PS, Petersen RC, Donohue MC et al (2010) Clinical Core of the Alzheimer’s Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement 6:239–246PubMedPubMedCentralCrossRef

Cai S, Huang L, Zou J et al (2015) Changes in thalamic connectivity in the early and late stages of amnestic mild cognitive impairment: a resting-state functional magnetic resonance study from ADNI. PLoS ONE 10:e0115573PubMedPubMedCentralCrossRef

Weiner MW, Veitch DP, Aisen PS et al (2015) 2014 Update of the Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer’s Dementia 11:e1-120PubMedCrossRef

Jessen F, Wolfsgruber S, Wiese B et al (2014) AD dementia risk in late MCI, in early MCI, and in subjective memory impairment. Alzheimer’s Dementia 10:76–83PubMedCrossRef

Edmonds EC, McDonald CR, Marshall A et al (2019) Early versus late MCI: Improved MCI staging using a neuropsychological approach. Alzheimer’s Dementia 15:699–708PubMedCrossRef

Jitsuishi T, Yamaguchi A (2022) Searching for optimal machine learning model to classify mild cognitive impairment (MCI) subtypes using multimodal MRI data. Sci Rep 12:4284ADSPubMedPubMedCentralCrossRef

10.

Zamani J, Sadr A, Javadi AH (2022) Classification of early-MCI patients from healthy controls using evolutionary optimization of graph measures of resting-state fMRI, for the Alzheimer’s disease neuroimaging initiative. PLoS ONE 17:e0267608PubMedPubMedCentralCrossRef

11.

Mesulam MM (2013) Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer’s disease. J Comparative Neurol 521:4124–4144CrossRef

12.

Schmitz TW, Mur M, Aghourian M, Bedard M-A, Spreng RN (2018) Longitudinal Alzheimer’s Degeneration Reflects the Spatial Topography of Cholinergic Basal Forebrain Projections. Cell Rep 24:38–46PubMedPubMedCentralCrossRef

13.

Arendt T, Brückner MK, Morawski M, Jäger C, Gertz H-J (2015) Early neurone loss in Alzheimer’s disease: cortical or subcortical? Acta Neuropathol Commun 3:1–11CrossRef

14.

Baker-Nigh A, Vahedi S, Davis EG et al (2015) Neuronal amyloid-β accumulation within cholinergic basal forebrain in ageing and Alzheimer’s disease. Brain 138:1722–1737PubMedPubMedCentralCrossRef

15.

Braak H, Del Tredici K (2015) The preclinical phase of the pathological process underlying sporadic Alzheimer’s disease. Brain 138:2814–2833PubMedCrossRef

16.

Schmitz T, Nathan Spreng R (2016) Alzheimer’s Disease Neuroimaging I (2016) Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology. Nat Commun 7:13249ADSPubMedPubMedCentralCrossRef

17.

Kondo H, Zaborszky L (2016) Topographic organization of the basal forebrain projections to the perirhinal, postrhinal, and entorhinal cortex in rats. J Comparative Neurol 524:2503–2515CrossRef

18.

Fernández-Cabello S, Kronbichler M, Van Dijk KRA et al (2020) Basal forebrain volume reliably predicts the cortical spread of Alzheimer’s degeneration. Brain 143:993–1009PubMedPubMedCentralCrossRef

19.

Castellano JM, Kim J, Stewart FR et al (2011) Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance. Sci Translat Med 3:89ra57-89ra57CrossRef

20.

Chai AB, Lam HHJ, Kockx M, Gelissen IC (2021) Apolipoprotein E isoform-dependent effects on the processing of Alzheimer's amyloid-β. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1866:158980 https://doi.org/10.1016/j.bbalip.2021.158980

21.

Chen Z-R, Huang J-B, Yang S-L, Hong F-F (2022) Role of Cholinergic Signaling in Alzheimer & Disease. Molecules 27:1816PubMedPubMedCentralCrossRef

22.

Ramos-Rodriguez JJ, Pacheco-Herrero M, Thyssen D et al (2013) Rapid β-Amyloid Deposition and Cognitive Impairment After Cholinergic Denervation in APP/PS1 Mice. J Neuropathol Exp Neurol 72:272–285PubMedCrossRef

23.

Hampel H, Mesulam M-M, Cuello AC et al (2018) The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain 141:1917–1933PubMedPubMedCentralCrossRef

24.

Hoskin JL, Al-Hasan Y, Sabbagh MN (2018) Nicotinic Acetylcholine Receptor Agonists for the Treatment of Alzheimer’s Dementia: An Update. Nicotine Tob Res 21:370–376PubMedCentralCrossRef

25.

Bott JB, Héraud C, Cosquer B et al (2016) APOE-Sensitive Cholinergic Sprouting Compensates for Hippocampal Dysfunctions Due to Reduced Entorhinal Input. J Neurosci 36:10472–10486PubMedPubMedCentralCrossRef

26.

Weiner MW, Veitch DP, Aisen PS et al (2012) The Alzheimer’s Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimer’s Dementia 8:S1–S68PubMedCrossRef

27.

Crane PK, Carle A, Gibbons LE et al (2012) Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav 6:502–516PubMedPubMedCentralCrossRef

28.

Gibbons LE, Carle AC, Mackin RS et al (2012) A composite score for executive functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav 6:517–527PubMedPubMedCentralCrossRef

29.

Eickhoff SB, Stephan KE, Mohlberg H et al (2005) A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data. Neuroimage 25:1325–1335PubMedCrossRef

30.

Anthoula T, Marianna S, Penelope M et al (2018) Co morbidity and neuroimaging in Alzheimer’s. Gerontology & Geriatrics Studies. https://scholar.google.com.tw/scholar?hl=zh-TW&as_sdt=0%2C5&q=Anthoula+T%2C+Marianna+S%2C+Penelope+M+et+al+%282018%29+Co+morbidity+and+Neuroimaging+in+Alzheimer%E2%80%99s.+Gerontology+%26+Geriatrics+Studies

31.

Zaborszky L, Hoemke L, Mohlberg H, Schleicher A, Amunts K, Zilles K (2008) Stereotaxic probabilistic maps of the magnocellular cell groups in human basal forebrain. Neuroimage 42:1127–1141PubMedCrossRef

32.

Gaser C, Kurth F (2017) Manual computational anatomy toolbox-CAT12. University of Jena, Structural brain mapping Group at the Departments of Psychiatry and Neurology

33.

Nemoto K, Dan I, Rorden C et al (2011) Lin4Neuro: a customized Linux distribution ready for neuroimaging analysis. BMC Med Imaging 11:3–3PubMedPubMedCentralCrossRef

34.

Núñez C, Callén A, Lombardini F, Compta Y, Stephan-Otto C, AsDN I (2020) Different cortical gyrification patterns in Alzheimer’s disease and impact on memory performance. Ann Neurol 88:67–80PubMedCrossRef

35.

Gaser C, Dahnke R, Thompson PM, Kurth F, Luders E, Initiative AsDN (2022) CAT – A Computational Anatomy Toolbox for the Analysis of Structural MRI Data. bioRxiv. https://doi.org/10.1101/2022.06.11.495736:2022.2006.2011.495736

36.

Smith SM, Nichols TE (2009) Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 44:83–98PubMedCrossRef

37.

Cortes C, Vapnik V (1995) Support-vector networks Machine learning 20:273–297

38.

Camps-Valls G, Gómez-Chova L, Calpe-Maravilla J et al (2004) Robust support vector method for hyperspectral data classification and knowledge discovery. IEEE Trans Geosci Remote Sens 42:1530–1542ADSCrossRef

39.

Guo S, Lai C, Wu C et al (2017) Conversion discriminative analysis on mild cognitive impairment using multiple cortical features from MR images. Front Aging Neurosci 9:146PubMedPubMedCentralCrossRef

40.

Bisong E (2019) Building machine learning and deep learning models on Google cloud platform. SpringerCrossRef

41.

Paper (2020) Hands-on Scikit-Learn for Machine Learning Applications. Apress https://doi.org/10.1007/978-1-4842-5373-1

42.

Garreta R, Moncecchi G (2013) Learning scikit-learn: machine learning in python. Packt Publishing Ltd. https://scholar.google.com.tw/scholar?hl=zh-TW&as_sdt=0%2C5&q=Garreta+R%2C+Moncecchi+G+%282013%29+Learning+scikit-learn%3A+machine+learning+in+python.+Packt+Publishing+Ltd&btnG=

43.

DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845PubMedCrossRef

44.

Bachli MB, Sedeño L, Ochab JK et al (2020) Evaluating the reliability of neurocognitive biomarkers of neurodegenerative diseases across countries: A machine learning approach. Neuroimage 208:116456PubMedCrossRef

45.

Liu Y, Tan L, Wang H-F et al (2016) Multiple effect of APOE genotype on clinical and neuroimaging biomarkers across Alzheimer’s disease spectrum. Mol Neurobiol 53:4539–4547PubMedCrossRef

46.

Jack CR Jr, Knopman DS, Jagust WJ et al (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. The Lancet Neurology 9:119–128PubMedPubMedCentralCrossRef

47.

Lim YY, Laws SM, Villemagne VL et al (2016) Aβ-related memory decline in APOE ε4 noncarriers: Implications for Alzheimer disease. Neurology 86:1635–1642PubMedCrossRef

48.

Bekdash RA (2021) The Cholinergic System, the Adrenergic System and the Neuropathology of Alzheimer’s Disease. Int J Mol Sci 22:1273PubMedPubMedCentralCrossRef

49.

Schmitz TW, Soreq H, Poirier J, Spreng RN (2020) Longitudinal basal forebrain degeneration interacts with trem2/c3 biomarkers of inflammation in presymptomatic Alzheimer’s disease. J Neurosci 40:1931–1942PubMedPubMedCentralCrossRef

50.

La Joie R, Bejanin A, Fagan AM et al (2018) Associations between [18F] AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology 90:e282–e290PubMedPubMedCentral

51.

Suzuki K, Hirakawa A, Ihara R et al (2020) Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer’s disease. Alzheimer’s Dementia: Translat Res Clin Interventions 6:e12007CrossRef

52.

O’Donoghue MC, Murphy SE, Zamboni G, Nobre AC, Mackay CE (2018) APOE genotype and cognition in healthy individuals at risk of Alzheimer’s disease: A review. Cortex 104:103–123PubMedCrossRef

Titel: Atrophy of the cholinergic regions advances from early to late mild cognitive impairment
verfasst von: Ying-Liang Larry Lai
Fei-Ting Hsu
Shu-Yi Yeh
Yu-Tzu Kuo
Hui-Hsien Lin
Yi-Chun Lin
Li-Wei Kuo
Cheng-Yu Chen
Hua-Shan Liu
for the Alzheimer’s Disease Neuroimaging Initiative
Publikationsdatum: 19.01.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Neuroradiology / Ausgabe 4/2024
Print ISSN: 0028-3940
Elektronische ISSN: 1432-1920
DOI: https://doi.org/10.1007/s00234-024-03290-6

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2024

European Society of Neuroradiology (ESNR)

Removing outliers from the normative database improves regional atrophy detection in single-subject voxel-based morphometry

Assessing the effect of oral glutamine on the MELAS phenotype requires appropriate study designs

Whole-tumor histogram analysis of postcontrast T1-weighted and apparent diffusion coefficient in predicting the grade and proliferative activity of adult intracranial ependymomas

Use of the pRESET LITE thrombectomy device in combined approach for medium vessel occlusions: A multicenter evaluation